Med-X | Wearable vagus nerve stimulation paves the way for personalized depression treatment

Major depressive disorder affects more than 280 million people worldwide and remains a major challenge to global mental health. Despite advances in antidepressant medications and psychotherapy, many patients continue to experience inadequate treatment responses. Vagus nerve stimulation (VNS) has emerged as a promising neuromodulation strategy, particularly for treatment-resistant depression. However, conventional implantable systems require surgery and specialized medical care, limiting their accessibility. Recent advances in wearable bioelectronics are creating new opportunities for non-invasive, home-based neuromodulation and offering a potential pathway toward more personalized depression care.

Recently, a comprehensive review titled "Wearable vagus nerve stimulation for depression: mechanisms, devices, and the road toward personalized neuromodulation" was published in Med-X. The review systematically summarizes the biological mechanisms underlying wearable non-invasive VNS (wnVNS), examines emerging device technologies and clinical evidence, and highlights future opportunities for personalized neuromodulation through multimodal sensing and artificial intelligence (AI).

1. Biological Mechanisms: Understanding the Antidepressant Effects of VNS

The vagus nerve serves as a major communication pathway between the brain and peripheral organs, regulating emotional, autonomic, and immune functions. By activating vagal pathways, wnVNS may influence several interconnected biological processes involved in depression. These include modulation of neurotransmitters such as serotonin and norepinephrine, enhancement of brain-derived neurotrophic factor (BDNF)-associated neuroplasticity, and suppression of inflammatory responses through the cholinergic anti-inflammatory pathway. In addition, neuroimaging studies suggest that VNS can regulate functional connectivity within brain networks associated with emotional processing and cognitive control. Together, these mechanisms indicate that the potential antidepressant effects of wnVNS arise from coordinated interactions among neural, immune, and autonomic systems.

2. Wearable Technologies: Advancing Non-invasive Neuromodulation

Building on these mechanistic insights, wearable bioelectronics have enabled the development of non-invasive alternatives to conventional implantable VNS. Two major approaches are transcutaneous auricular VNS (taVNS), which targets vagal branches in the outer ear, and transcutaneous cervical VNS (tcVNS), which stimulates the cervical vagus nerve through the skin of the neck. Emerging devices, including earclips, earbuds, flexible patches, and neck-worn systems, aim to improve comfort, accessibility, and suitability for home-based treatment. Importantly, electrode configuration, stimulation parameters, and skin-electrode interactions directly influence neural activation and therapeutic responses. These engineering considerations are therefore essential for translating the biological potential of VNS into reliable wearable neuromodulation technologies

3. Clinical Evidence: Evaluating Therapeutic Potential and Limitations

As wearable VNS technologies continue to evolve, clinical studies have begun to explore their therapeutic potential for depression. Existing findings suggest that non-invasive stimulation may alleviate depressive symptoms while influencing physiological indicators such as heart rate variability and functional brain connectivity. However, the current evidence remains limited by relatively small study populations, heterogeneous stimulation protocols, and inconsistent outcome assessments. Moreover, the optimal stimulation parameters and long-term therapeutic benefits have yet to be fully established. Addressing these challenges will require larger, well-controlled clinical studies and greater standardization of device design and treatment protocols to improve reproducibility and support clinical translation.

4. Scholarly Value and Future Perspectives

This review highlights the potential of integrating wearable bioelectronics, multimodal physiological sensing, and AI-assisted closed-loop control to advance personalized depression treatment. By continuously monitoring neural and autonomic signals, future systems could dynamically adjust stimulation parameters according to individual physiological states and therapeutic responses. Such developments may enable a transition from fixed stimulation protocols toward adaptive, patient-centered neuromodulation. By connecting biological mechanisms, device engineering, and clinical evidence, the review provides a comprehensive perspective on the opportunities and challenges of wearable VNS and outlines promising directions for more accessible and personalized depression care.